

Serial No.: 08/167,846
Group Art Unit No.: 1201

Please amend the remaining claims, as follows:

claim 19, line 3, delete "claim 44" and insert --claim 16--;
claim 20, line 1, delete "claim 44" and insert --claim 19--;
claim 21, line 1, delete "claim 44" and insert --claim 19--;
claim 22, line 1, delete "claim 44" and insert --claim 19--; and
claim 23, line 1, delete "claim 44" and insert --claim 19--.

REMARKS

This Amendment is being made after the mailing of the Notice of Allowance and Issue Fee Due and further to the Amendment After Allowance Under 37 C.F.R. §312(a) facsimile transmitted on July 24, 1995 in this application. By this amendment, allowed claims 1-15 and 17-18 have been canceled without prejudice to their further prosecution in one or more continuation applications. Accordingly, claims 16, 19 and 20-23 remain pending in this application.

In addition, the undersigned attorney has reviewed the application at this time and is submitting this Amendment under 37 C.F.R. §1.312(a) in order to correct the dependency in each of claims 19, 20, 21, 22 and 23. Originally, method of treatment claims 20, 21, 22 and 23 were dependent on compound claim 16. Clearly these claims should have been dependent on a method of treatment claim and not a compound claim. This inadvertent error is being corrected by the Amendment herein which amends claims 20-23 to depend from claim 19 which is a method of treatment claim directed to the treatment of a condition wherein a 5-HT₁-like agonist is indicated with an effective amount of a compound of claim 16. It is urged that none of the amendments submitted herein introduce any new matter into the application or change the scope of the previously allowed claims 16 and 19-23, but merely place the application in better condition for its issuance into a patent.


No fee is deemed necessary by this Amendment, however, the Commissioner is hereby authorized to charge any fee necessary to Deposit Account No. 19-2750.

Serial No.: 08/167,846
Group Art Unit No.: 1201

In view of the foregoing, it is respectfully requested that this Amendment be entered without withdrawing the application from issue, and that a patent with claims 16 and 19-23 be issued.

Respectfully submitted,

By:


Nora Stein-Fernandez
Attorney for Applicants
Registration No. 36,689

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5044
Facsimile (610) 270-5090

n:\nsf\patapp\p30104\312amd2.doc